- Jun 23 2015 ·
Multi-targeted small molecule therapy to treat Alzheimer’s disease!
Amarit Biosciences is an innovative drug discovery company and focuses on novel chemistry based technologies to discover multi-targeted single-small molecule therapeutics for neurodegenerative disorders, especially Alzheimer’s disease (AD), for which there are no disease modifying or curative treatments yet.
- Jun 22 2015 ·
Spindletop Capital – Partners with exceptional leaders to build transformational healthcare companies.
Spindletop Capital focuses exclusively on healthcare investment opportunities. They strategically invest in companies – both within the region and nationally.
- Healthcare Services and Distribution
- Biopharma and Specialty Pharmaceuticals
- Healthcare IT
- Medical Diagnostics and Devices
- Jun 22 2015 ·
Amino, the tamagotchi for synthetic biology!
Amino is an intuitive bioengineering mini-lab that allows easy bacterial transformations and enables continuous growth of the culture. Inspired by tamagotchis, the genetic transformation of an organism´s DNA is performed by the user through guided interactions, resulting in their own synthetic organism, for which they can care for like you would a pet.
- Jun 19 2015 ·
Your new standard to evaluate the systemic toxicity of cosmetic products!
CeleScreen offers an innovative alternative method to characterize the toxicity of cosmetic molecules, at the scale of a whole organism via the worm C elegans.
Since 2013 cosmetics regulation prohibits the realization of tests being important to evaluate toxicity on vertebrate animals.
By offering an optimal toxicological model at the organism scale with a scale-up technology CeleScreen represents a strong interest for cosmetics industrials!
- Jun 18 2015 ·
Improvement of pastures for a more sustainable livestock production!
The company´s product GRAMAX is a subtropical pasture of the variety Rhode Grass, molecularly enhanced to increase its forage quality.
Its main feature is a higher digestibility.
This allows increasing the efficiency of animal feed, positively impacting productivity while reducing greenhouse gases emissions of produced meat.
- Jun 17 2015 ·
Keep up with BIOStartr and the biotech and startup scene and sign up to our weekly newsletter!
Take a look at this week’s BIOStartr newsletter here and subscribe now to get your weekly update
In this Issue
- Meet your target audience on BIOStartr – Register your biotech on BIOStartr and benefit from the BIOStartr ecosystem consisting if investors and supporters worldwide
- New biotechs on BIOStartr – BIOStartr welcomes Anew green, RMD Biotech and Farm4Trade, three promising biotechs
- New BIOStartr partner – BIOStartr teams up with BioRiver
- What is the main cause of death for 90% of startups? – See the 20 biggest reasons why startup companies fail
- Weekly biotech news – BIOStartr provides you with the most important headlines regarding biotech and startups of this week
- Jun 17 2015 ·
Unleash the power of cell-free DNA!
Freenome is a technology company developing proprietary algorithms and novel methods to enable accurate diagnosis of clinical conditions. The platform utilizes the power of next-generation sequencing to bring about the dream of non-invasive, accurate and early detection of cancer…from 1 mL of blood.
Method: Extraction of circulating, cell-free DNA (cfDNA) that are expelled by the cells in the body from a sample of your blood. Tumor cells expel cfDNA with mutations associated with cancer called circulating tumor DNA (ctDNA).
- Jun 16 2015 ·
EvoRx has developed a revolutionary technology that enables the development of next generation treatments for today’s unmet therapeutic needs.
EvoRx can design orally available, cell permeable compounds to drug protein-protein interactions that were thought to be undruggable!
For more information about that highly innovative company have a look here
- Jun 15 2015 ·
Novel treatments for chronic viral infections!
ContraVir is developing targeted antiviral therapies with two drug candidates in clinical studies. FV-100, now in a pivotal Phase 3 trials, is a novel therapeutic drug candidate to treat herpes zoster, or shingles. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®).
Read more about the opportunities of these drug candidates on http://contravir.com